In addition to L-asparaginase, we plan to leverage the broad applicability of our ERYCAPS® platform to develop additional novel product candidates.
We have identified two other amino acid metabolism targeting enzymes, methionine-γ-lyase (MGL) and arginine deiminase (ADI), which we believe can benefit from being encapsulated in red blood cells. MGL and ADI degrade methionine and arginine respectively, two essential amino acids that are necessary for tumor cells to survive and proliferate.
Erymethionase, MGL encapsulated in red blood cells, is a product candidate which is currently in preclinical development. We intend to continue to work on the development of erymethionase as well as potential other therapeutic strategies based on methionine depletion, depending on financial resources and business strategy.